A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure

Eur J Cardiothorac Surg. 2012 Jun;41(6):1377-83. doi: 10.1093/ejcts/ezr201. Epub 2011 Dec 23.

Abstract

Objectives: Levosimendan is a novel inotropic agent claimed to improve myocardial contractility by a calcium-sensitizing effect. Our aim was to evaluate dose-dependent effects of levosimendan on left ventricular (LV) contractility and energetic properties in an acute, ischaemic heart failure porcine model.

Methods: Six pigs were used in an anaesthetized in vivo open-chest model. The time points of measurements were: baseline, after heart failure induction and after dose 1-4 (D1-D4). Heart failure was induced by microembolization of the left coronary artery before infusion of four different doses (D1: 2.5 µg/kg, D2: 10 µg/kg, D3: 40 µg/kg, D4: 80 µg/kg) of levosimendan. Haemodynamics were assessed by the pressure-conductance catheter technique. LV oxygen consumption was calculated from coronary flow measurements and coronary sinus blood gases. Mitochondrial respiration was studied in biopsies of the LV.

Results: Levosimendan had no significant, load-independent effect on contractile force (slope of preload recruitable stroke work was 34 mmHg immediately following failure and 39 (P = 0.406), 42 (P = 0.219), 46 (P = 0.067) and 41 (P = 0.267) at D1-D4), although the more load-dependent contractility indicator of dP/dt(max) was slightly increased at dose 4 (P < 0.05). LV energy conversion efficiency (PVA-MVO2 relationship) remained unaltered at all doses. Maximal mitochondrial respiration decreased after induction of failure and remained at an unaltered low level during levosimendan infusion.

Conclusions: Surprisingly, levosimendan had no significant effect on contractility, energy efficiency and mitochondrial respiration of the LV, in a porcine model of acute heart failure. At high doses, levosimendan induced vasodilatation and increased heart rate and cardiac output.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiotonic Agents / administration & dosage*
  • Cardiotonic Agents / pharmacology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Heart Failure / etiology
  • Heart Failure / physiopathology*
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Hydrazones / administration & dosage*
  • Hydrazones / pharmacology
  • Mitochondria, Heart / drug effects
  • Mitochondria, Heart / physiology
  • Myocardial Contraction / drug effects
  • Myocardial Contraction / physiology
  • Oxygen Consumption / drug effects
  • Oxygen Consumption / physiology
  • Pyridazines / administration & dosage*
  • Pyridazines / pharmacology
  • Simendan
  • Sus scrofa
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology

Substances

  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan